Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aclaris Therapeutics, Inc. ACRS
$7.99
-$0.03 (-0.37%)
На 18:00, 12 мая 2023
+212.89%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
568615773.00000000
-
week52high
18.96
-
week52low
5.77
-
Revenue
29752000
-
P/E TTM
-7
-
Beta
0.52110700
-
EPS
-1.30000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:00
Описание компании
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 16 июн 2021 г. |
| Piper Sandler | Overweight | 15 июн 2021 г. | |
| HC Wainwright & Co. | Buy | 21 апр 2021 г. | |
| SVB Leerink | Outperform | Outperform | 04 мар 2021 г. |
| SVB Leerink | Outperform | Outperform | 20 янв 2021 г. |
| BTIG | Buy | 06 окт 2022 г. | |
| Goldman Sachs | Buy | 01 дек 2022 г. | |
| Stifel | Buy | 14 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Walker Neal | D | 1175763 | 200 | 02 февр 2023 г. |
| Walker Neal | D | 1175963 | 3121 | 02 февр 2023 г. |
| Walker Neal | D | 1179084 | 600 | 02 февр 2023 г. |
| Walker Neal | D | 1179684 | 1079 | 02 февр 2023 г. |
| Walker Neal | D | 1180763 | 25000 | 01 февр 2023 г. |
| Monahan Joseph | A | 30000 | 30000 | 01 февр 2023 г. |
| Monahan Joseph | A | 105000 | 105000 | 01 февр 2023 г. |
| Manion Douglas J. | A | 108000 | 108000 | 01 февр 2023 г. |
| Manion Douglas J. | A | 378000 | 378000 | 01 февр 2023 г. |
| Loerop James | D | 33750 | 11250 | 01 февр 2023 г. |
Новостная лента
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 09:54
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.31 per share a year ago.
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
GlobeNewsWire
02 мая 2023 г. в 07:01
WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2023 on Monday, May 8, 2023, before the opening of the U.S. financial markets.
3 Biotech Stocks to Sell Before They're 6 Feet Under
InvestorPlace
24 апр 2023 г. в 14:37
In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D.
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
GlobeNewsWire
27 мар 2023 г. в 07:00
WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET.
These 2 Biotech Stocks Made Big Monday Moves
The Motley Fool
06 мар 2023 г. в 14:32
Markets were mixed, with large caps rising as small caps gave up ground. BridgeBio Pharma showed positive trial results for a treatment for a disease that limits growth.